AU2010211289B2 - Vector(s) containing an inducible gene encoding a CDK4/CDK6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle - Google Patents

Vector(s) containing an inducible gene encoding a CDK4/CDK6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle Download PDF

Info

Publication number
AU2010211289B2
AU2010211289B2 AU2010211289A AU2010211289A AU2010211289B2 AU 2010211289 B2 AU2010211289 B2 AU 2010211289B2 AU 2010211289 A AU2010211289 A AU 2010211289A AU 2010211289 A AU2010211289 A AU 2010211289A AU 2010211289 B2 AU2010211289 B2 AU 2010211289B2
Authority
AU
Australia
Prior art keywords
vector
expression
cell
gene
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010211289A
Other languages
English (en)
Other versions
AU2010211289A1 (en
Inventor
Thomas Arendt
Uwe Ueberham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leipzig University
Original Assignee
Leipzig University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leipzig University filed Critical Leipzig University
Publication of AU2010211289A1 publication Critical patent/AU2010211289A1/en
Application granted granted Critical
Publication of AU2010211289B2 publication Critical patent/AU2010211289B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010211289A 2009-02-04 2010-02-04 Vector(s) containing an inducible gene encoding a CDK4/CDK6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle Ceased AU2010211289B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09001521A EP2218784A1 (en) 2009-02-04 2009-02-04 Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders
EP09001521.5 2009-02-04
PCT/EP2010/000702 WO2010089122A2 (en) 2009-02-04 2010-02-04 Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle

Publications (2)

Publication Number Publication Date
AU2010211289A1 AU2010211289A1 (en) 2011-09-01
AU2010211289B2 true AU2010211289B2 (en) 2016-12-15

Family

ID=40673417

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010211289A Ceased AU2010211289B2 (en) 2009-02-04 2010-02-04 Vector(s) containing an inducible gene encoding a CDK4/CDK6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle

Country Status (8)

Country Link
US (2) US20120004277A1 (enExample)
EP (2) EP2218784A1 (enExample)
JP (1) JP5869884B2 (enExample)
KR (1) KR101378353B1 (enExample)
CN (1) CN102356156A (enExample)
AU (1) AU2010211289B2 (enExample)
CA (1) CA2751531A1 (enExample)
WO (1) WO2010089122A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653324B2 (en) * 2010-06-11 2014-02-18 Fox Chase Cancer Center TetO-p16 transgenic mice
WO2012050975A2 (en) * 2010-09-29 2012-04-19 The University Of North Carolina At Chapel Hill Novel circular mammalian rna molecules and uses thereof
KR101255338B1 (ko) * 2010-12-15 2013-04-16 포항공과대학교 산학협력단 표적 세포에 대한 폴리뉴클레오티드 전달체
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN108319816B (zh) * 2018-02-27 2021-04-23 广州大学 一种基于基因通路识别小分子核糖核酸的方法
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117769A1 (en) * 2003-09-29 2007-05-24 Maines Mahin D Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase
WO2011025566A1 (en) * 2009-08-26 2011-03-03 Shi-Lung Lin Development of universal cancer drugs and vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19936034C1 (de) * 1999-07-30 2001-01-25 Univ Leipzig Rekombiniertes, neuronalspezifisch aktiviertes, transkribierbares lineares DNA-Konstrukt
ATE478965T1 (de) * 2004-07-21 2010-09-15 Dana Farber Cancer Inst Inc Lentivirusvektoren und deren verwendung
EP1838841A2 (en) * 2004-12-23 2007-10-03 The Ludwig Institute for Cancer Research Engineered dopamine neurons and uses thereof
US20080300202A1 (en) * 2006-05-18 2008-12-04 The State of Oregon acting by and through the State Board of Higher Education on behalf of the Subtractive transgenics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117769A1 (en) * 2003-09-29 2007-05-24 Maines Mahin D Methods of modulating cell cycle and cell signaling pathways using biliverdin reductase
WO2011025566A1 (en) * 2009-08-26 2011-03-03 Shi-Lung Lin Development of universal cancer drugs and vaccines

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEN., X., ET AL., 'Senescence-like changes induced by expression of p21Waf1/Cip1 in NIH3T3 cell line', Cell Research, 2002, vol. 12, no. 3-4, pages 229-33. *
DIRKS, P., ET AL., 'Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells', Oncogene, 1997, vol. 15, no. 17, pages 2037-48. *
GIOVANNI, A., ET AL., 'Involvement of cell cycle elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal death', The Journal of Biological Chemistry, 1999, vol. 274, no. 27, pages 19011-6 *
GOUKASSIAN, D., ET AL., 'Overexpression of p27Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis', The FASEB Journal, 2001, vol. 15, no. 11 , pages 1877-85. *
NGUYEN, M., ET AL., 'Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1', The Journal of Neuroscience, 2003, vol. 23, no. 6, pages 2131-40. *
RIDEOUT, H., ET AL., 'Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition', The Journal of Neuroscience, 2003, vol. 23, no. 4, pages 1237-45 *
ROSSI, F., ET AL., 'Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16', Nature Genetics, 1998, vol. 20, no. 4, pages 389-93. *
UEBERHAM, E., ET AL., 'Oval cell proliferation in p16Ink4a expressing mouse liver is triggered by chronic growth stimuli', Journal of Cellular and Molecular Medicine, 2008, vol. 12, no. 2, pages 622-38. *
UHRBOM, L., ET AL., 'Induction of senescence in human malignant glioma cells by p16Ink4a', Oncogene, 1997, vol. 15, no. 5, pages 505-14. *

Also Published As

Publication number Publication date
EP2620447B1 (en) 2015-09-09
EP2620447A1 (en) 2013-07-31
US20160144054A1 (en) 2016-05-26
KR101378353B1 (ko) 2014-04-10
WO2010089122A2 (en) 2010-08-12
WO2010089122A3 (en) 2010-12-09
EP2218784A1 (en) 2010-08-18
AU2010211289A1 (en) 2011-09-01
JP5869884B2 (ja) 2016-02-24
KR20110121704A (ko) 2011-11-08
JP2012516691A (ja) 2012-07-26
US20120004277A1 (en) 2012-01-05
CA2751531A1 (en) 2010-08-12
CN102356156A (zh) 2012-02-15

Similar Documents

Publication Publication Date Title
US20160144054A1 (en) Vector(S) Containing an Inducible Gene Encoding a CDK4/CDK6 Inhibitor Useful for Treating Neurodegenerative Disorders or Diseases Associated with an Unscheduled Activation of the Cell Cycle
TWI787163B (zh) 用於減少tau表現之組合物及方法
US8389487B2 (en) siRNA-mediated gene silencing of synuclein
CN114174520A (zh) 用于选择性基因调节的组合物和方法
CN113544267A (zh) 使用CRISPR-Cas进行靶向核RNA裂解和聚腺苷酸化
US12103952B2 (en) Methods for expressing proteins in axons
KR20140123054A (ko) 생물학적 활성 ｒｎａ의 전달을 위한 조성물 및 방법
JP2019503205A (ja) 自己切断リボザイムのアプタマー媒介性制御を通じての遺伝子発現制御
JP2022536606A (ja) タウオパチーのモデル
CN116113697A (zh) 用于治疗癫痫的方法和组合物
CN116490615A (zh) 工程化CRISPR-Cas13f系统及其用途
WO2016134293A1 (en) p63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
FI120942B (fi) Menetelmä kaksoissäikeisen nukleiinihapon valmistamiseksi
US11566247B2 (en) Modulation of alternative MDM2 splicing
CN103370414A (zh) 降低恶性神经胶质瘤中下调肾细胞癌的表达的方法
Reza et al. Triplex-mediated genome targeting and editing
Wang et al. Lentivector-mediated RNAi efficiently downregulates expression of murine TNF-α gene in vitro and in vivo
JP2018515110A (ja) 多発性硬化症の治療
HK40118673A (en) Therapeutic factors for the treatment of polyq diseases
HK40094999B (zh) 工程化cas12b效应蛋白及其使用方法
HK40094999A (en) Engineered cas12b effector proteins and methods of use thereof
WO2003070932A1 (en) Polynucleotide for target gene
Hung Combined gene therapy of siRNA and apoptosis inducing factor generated from a single transcriptional event
Scaria et al. 522. Increased Expression of OCT4, SOX2 and FGF4 Genes Following Injection of Embryonic Stem Cell into Damaged Murine Brain

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired